Home › Funds › Sender Co & Partners, Inc. › VKTX

Sender Co & Partners, Inc. position in VKTX

VIKING THERAPEUTICS INC · Health Care

Sender Co & Partners, Inc. reported holding 31,400 shares of VKTX (VIKING THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.0M, representing 0.47% of its reported portfolio and ranking #40 among its reported holdings. Sender Co & Partners, Inc. has disclosed VKTX holdings in 5 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)31.40K sh
Reported value held$1.02M
Portfolio Weight0.47%
First reportedQ2 2025
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Sender Co & Partners, Inc.'s VKTX position evolved

Sender Co & Partners, Inc. first disclosed a stake in VKTX in Q2 2025 at 57,600 shares (US$1.5M). The position peaked in Q2 2026 at 166,600 shares, worth US$6.5M. Across 5 filings, Sender Co & Partners, Inc. increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 31,400 shares valued at US$1.0M — a reduction of -135,200 shares quarter over quarter.. Notable position changes include a 932% increase in Q2 2026 (shares fell 16% over the following quarter), a 81% trim in Q3 2026 (shares fell 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 57.60K $1.53M New
Q4 2025 19.84K $697.83K New
Q1 2026 16.14K $525.07K Reduce
Q2 2026 166.60K $6.50M Add
Q3 2026 31.40K $1.02M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VKTX and 13F data

VKTX (VIKING THERAPEUTICS INC) is a Health Care company. 30 other funds we track also report a position in VKTX — the largest reported positions include Context Capital Management, LLC (US$39.9M), Vestal Point Capital, LP (US$26.5M), Eversept Partners, LP (US$23.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VKTX

All VKTX fund holders →

FAQ

How long has Sender Co & Partners, Inc. held VKTX?

Sender Co & Partners, Inc. has disclosed VKTX holdings in 5 of the last 6 reported quarters, going back to Q2 2025.

What is Sender Co & Partners, Inc.'s current position in VKTX?

As of Q3 2026, Sender Co & Partners, Inc. holds 31.40K shares of VKTX (VIKING THERAPEUTICS INC), valued at $1.02M, representing 0.47% of its reported portfolio and ranking #40.

Has Sender Co & Partners, Inc. been buying or selling VKTX?

In the latest 13F filing (Q3 2026), Sender Co & Partners, Inc. reduced its position in VKTX. The position peaked in Q2 2026 at 166.60K shares.

Which other funds hold VKTX?

Other major institutional holders of VKTX include Context Capital Management, LLC, Vestal Point Capital, LP, Eversept Partners, LP, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.